- Home
- MGNX vs LSBK Comparison
MGNX vs LSBK Comparison
Compare MGNX & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- LSBK
- Stock Information
- Founded
- MGNX 2000
- LSBK 1891
- Country
- MGNX United States
- LSBK United States
- Employees
- MGNX N/A
- LSBK N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- LSBK Savings Institutions
- Sector
- MGNX Health Care
- LSBK Finance
- Exchange
- MGNX Nasdaq
- LSBK Nasdaq
- Market Cap
- MGNX 99.7M
- LSBK 101.4M
- IPO Year
- MGNX 2013
- LSBK 2006
- Fundamental
- Price
- MGNX $1.86
- LSBK $13.65
- Analyst Decision
- MGNX Hold
- LSBK
- Analyst Count
- MGNX 6
- LSBK 0
- Target Price
- MGNX $3.20
- LSBK N/A
- AVG Volume (30 Days)
- MGNX 726.3K
- LSBK 23.3K
- Earning Date
- MGNX 11-04-2025
- LSBK 10-22-2025
- Dividend Yield
- MGNX N/A
- LSBK 2.64%
- EPS Growth
- MGNX N/A
- LSBK 61.02
- EPS
- MGNX N/A
- LSBK 1.20
- Revenue
- MGNX $165,495,000.00
- LSBK $27,774,000.00
- Revenue This Year
- MGNX N/A
- LSBK N/A
- Revenue Next Year
- MGNX N/A
- LSBK N/A
- P/E Ratio
- MGNX N/A
- LSBK $11.42
- Revenue Growth
- MGNX 303.47
- LSBK 9.61
- 52 Week Low
- MGNX $0.99
- LSBK $11.50
- 52 Week High
- MGNX $5.10
- LSBK $13.69
- Technical
- Relative Strength Index (RSI)
- MGNX 55.15
- LSBK 72.17
- Support Level
- MGNX $1.82
- LSBK $12.50
- Resistance Level
- MGNX $2.15
- LSBK $12.99
- Average True Range (ATR)
- MGNX 0.13
- LSBK 0.18
- MACD
- MGNX 0.01
- LSBK 0.10
- Stochastic Oscillator
- MGNX 49.15
- LSBK 93.53
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.